A Study to HER2/neu Overexpression in Gastrointestinal Adenocarcinomas

Kalpana, R (2020) A Study to HER2/neu Overexpression in Gastrointestinal Adenocarcinomas. Masters thesis, Dhanalakshmi Srinivasan Medical College and Hospital, Perambalur.

[img]
Preview
Text
200345520kalpana.pdf

Download (3MB) | Preview

Abstract

BACKGROUND: Gastrointestinal malignancies are among major oncological problems worldwide, stomach cancer is the 5th and colorectal cancer is the 3rd most common cancer. The mortality rate of colorectal cancer is controllably low when compared to the gastric cancer. Diagnosis of gastrointestinal malignancies is usually made at advanced stages due to non-specific early symptoms of the disease. Therefore, it remains unresectable at the time of diagnosis. New molecular targets are constantly explored for effective management in the gastric and colorectal adenocarcinoma. One such target is HER2/neu receptor which already have antibody against it. Frequency of HER2/neu expression¹⁷ in gastric cancer has been reported from different geographic zones with a range of 6% to 35%. Conflicting data exist about the prevalence of HER2/neu overexpression in colorectal cancer ranging from 0 to 83%. AIMS AND OBJECTIVES: 1. Study of HER/2neu overexpression with emphasis on scoring in gastro intestinal tract adenocarcinomas by immunohistochemistry. 2. To assess the correlation of HER2/neu with histological grading of the tumor. METHODOLOGY: Relevant clinical details from prospective study while available details from retrospective study collected. Gastrointestinal adenocarcinomas tissue blocks retrieved from June 2012 for retrospective and from sept 2017 to August 2019 for prospective cases. HER2/neu overexpression was studied by immunohistochemistry. Expression of HER2/neu on malignant cells on all study cases evaluated using established criteria. Statistical analysis was performed by SPSS. RESULTS: In our study, a total of 50 cases were included; 28 cases from gastric adenocarcinomas and 22 cases from colorectal adenocarcinomas. HER2/neu positivity (3+ score) on immunohistochemistry was seen in 12 out of 50 gastrointestinal adenocarcinomas (24%). Among these, 58.33% were gastric cases and 41.67% were colorectal cases. HER2/neu positivity was found to be 25% (7 out of 28 cases) in gastric adenocarcinomas and 22.7% (5 out of 22 cases) in colorectal adenocarcinomas. In this study, we studied Her2/neu expression in 28 cases out of 50 cases of gastric carcinoma. The rate of Her2/neu positivity in our study is estimated to be about 25%in gastric adenocarcinoma. HER2/neu membranous positivity was found to be 22.7% (5 out of 22 cases) in colorectal adenocarcinomas. CONCLUSION: In our study, 50 specimens of gastrointestinal Adenocarcinomas were analysed. In gastric adenocarcinomas, HER2/neu positivity was found to be 28 % (7 out of 28 cases) and 22.7% (5 out of 22 cases) in colorectal adenocarcinomas. Overall, HER2/neu positivity (3+ score) on immunohistochemistry was seen in 12 out of 50 gastrointestinal adenocarcinomas (24%). Among these, 58.33% were gastric cases and 41.67% were colorectal cases. Most of the HER2/neu positivity was given by well differentiated tumour in our study and there was significant correlation of HER2/neu with grading of tumour (P value- 0.003). Gene amplification studies like FISH or PCR is essential for equivocal cases (2+) to know more about the role of oncogenesis of HER2/neu in gastrointestinal cancers.

Item Type: Thesis (Masters)
Additional Information: 201713652
Uncontrolled Keywords: HER2/neu, Gastric cancer, Colorectal cancer, Adenocarcinoma, Immunohistochemistry.
Subjects: MEDICAL > Pathology
Depositing User: Subramani R
Date Deposited: 29 Jan 2021 18:59
Last Modified: 29 Jan 2021 18:59
URI: http://repository-tnmgrmu.ac.in/id/eprint/13445

Actions (login required)

View Item View Item